Results 271 to 280 of about 1,375,213 (331)

Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. [PDF]

Proc Natl Acad Sci U S A
Ota N, Davies CW, Kang J, Yan D, Scherl A, Wong A, Cook R, Tao X, Dunlap D, Klabunde S, Mantik P, Mohanan V, Lin W, McBride J, Sadekar S, Storek KM, Lupardus P, Ye Z, Ackerly Wallweber H, Kiefer JR, Xu M, Chan P, Nagapudi K, Yi T, Koerber JT.   +24 more
europepmc   +1 more source

Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria

, 2004
Frank A. W. Verreck, Tjitske de Boer, Dennis M. L. Langenberg, Marieke A. Hoeve, Matthijs Kramer, Elena Vaisberg, Robert Kastelein, Arend J. Kolk, René de Waal Malefyt, Tom H. M. Ottenhoff   +9 more
openalex   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

IL-23 promotes neuronal ferroptosis via IL-23R/STAT3 signaling after traumatic brain injury. [PDF]

Cell Commun Signal
Chen B, Shi G, Xu J, Zhang X, Zhu Y, Li L, Wang C, Gheyret D, Wang J, Liu X, Cao Y, Tan R, Zhou Y, Jiang R, Li S, Li T, Liu X, Chen X, Yang G, Zhang J, Zhang S.   +20 more
europepmc   +1 more source

Il trapianto di rene tra viventi estranei: riflessioni biogiuridiche Commento al Parere del Comitato Nazionale per la Bioetica su “La donazione da vivo del rene a persone sconosciute (c.d. donazione samaritana)” del 23 aprile 2010

, 2010
Claudio Sartea
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

P1195 Identification of immune cell infiltration and potential candidate biomarker in anti-IL 12/23 treated Crohn’s disease patients by integrated bioinformatics analysis and machine learning [PDF]

Qin Li, Jian Tang, Kang Chao, Xiang Gao
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review. [PDF]

Therap Adv Gastroenterol
González Fernández J, Prieto-Torres L, Ara Martín M, Martínez-Domínguez SJ.   +3 more
europepmc   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source